Synapse - Adam Schoenfeld

Results (138)

Characteristics and outcomes of patients with SMARCA4-deficient undifferentiated thoracic tumors

Meeting Abstract

Cooper, A.; Ricciuti, B.; Gagne, A.; Sholl, L.; Di Federico, A.; Awad, M.; Aldea, M.; Ghigna, M. R.; Grecea, M.; Chaft, J.; more...
Journal of Thoracic Oncology (2024)

Fulltext@MSK | Save

Intratumoral escherichia is associated with improved survival to single-agent immune checkpoint inhibition in patients with advanced non–small-cell lung cancer

Journal Article

Elkrief, A.; Montesion, M.; Sivakumar, S.; Hale, C.; Bowman, A. S.; Begüm Bektaş, A.; Bradic, M.; Kang, W.; Chan, E.; Gogia, P.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Three-year overall survival outcomes and correlative analyses in patients with NSCLC and high (50%–89%) versus very high (≥90%) programmed death-ligand 1 expression treated with first-line pembrolizumab or cemiplimab

Journal Article

Ricciuti, B.; Elkrief, A.; Lin, J.; Zhang, J.; Alessi, J. V.; Lamberti, G.; Gandhi, M.; Di Federico, A.; Pecci, F.; Wang, X.; more...
JTO Clinical and Research Reports (2024)

Fulltext@MSK | Save

Efficacy and clinicogenomic biomarkers of response to dual versus single agent checkpoint inhibitor therapy in untreated metastatic non-small cell lung cancer

Meeting Abstract

Boiarsky, D.; Hong, L.; Ricciuti, B.; Cooper, A. J.; Saad, M. B.; Elkrief, A.; Di Federico, A.; Aminu, M.; Rinsurongkawong, W.; Lewis, J.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR, a CD8α/β coreceptor, and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors

Meeting Abstract

Mitchell, S.; Khan, B.; Payumo, F.; Chiorean, E. G.; Gahvari, Z.; Hecht, J. R.; Hurwitz, M. E.; Leidner, R.; Lenz, H. J.; Pelster, M.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Clinical outcomes and post-progression retreatment in patients with metastatic NSCLC who complete two years of treatment with immune checkpoint blockade

Meeting Abstract

Ricciuti, B.; Gariazzo, E.; Gorria, T.; Thummalapalli, R.; Citarella, F.; Gandhi, M. M.; Elkrief, A.; Pecci, F.; Alessi, J. V. M.; Di Federico, A.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced solid tumors

Meeting Abstract

Schoenfeld, A. J.; Warner, A. B.; Chesney, J. A.; Thomas, S. S.; Hamid, O.; In, G. K.; Shoushtari, A. N.; Samhouri, Y.; Hari, P. N.; Ramsingh, G.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

HLA associations with immunotherapy related endocrine toxicity

Meeting Abstract

Quandt, Z.; Thorball, C.; Middha, P.; Johnson, D. B.; Bejan, C. A.; Yao, L.; Xu, Y.; Hodel, F.; Stravodimou, A.; Shearer-Kang, E.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Multi-institution real world analysis of patients with non-small cell lung cancer (NSCLC) treated with standard of care (SOC) neoadjuvant chemo-immunotherapy (chemoIO)